Published in J Clin Oncol on May 01, 2007
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer (2008) 4.27
Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med (2009) 2.73
Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol (2008) 2.61
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29
The role of myosin II in glioma invasion of the brain. Mol Biol Cell (2008) 2.20
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest (2009) 1.78
Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol (2011) 1.64
Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One (2009) 1.40
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol (2009) 1.37
Integrin targeted therapeutics. Theranostics (2011) 1.36
Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging (2012) 1.33
Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol (2009) 1.27
Angiogenesis as a therapeutic target in malignant gliomas. Oncologist (2009) 1.23
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer (2012) 1.21
Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res (2008) 1.17
Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response (2010) 1.16
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol (2008) 1.16
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol (2009) 1.15
Integrin inhibitors reaching the clinic. J Clin Oncol (2007) 1.12
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res (2008) 1.10
Integrins and metastasis. Cell Adh Migr (2013) 1.08
New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med (2008) 1.08
PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem (2009) 1.08
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer (2011) 1.06
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol (2015) 1.06
Tumor angiogenesis: insights and innovations. J Oncol (2010) 1.04
Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. Br J Radiol (2011) 1.00
Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics (2009) 0.99
Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev (2008) 0.98
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2013) 0.97
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs (2012) 0.96
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs (2010) 0.95
Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway. J Natl Cancer Inst (2013) 0.94
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer (2011) 0.93
Integrin α3β1 as a breast cancer target. Expert Opin Ther Targets (2011) 0.93
Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev (2011) 0.93
Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts. Eur J Nucl Med Mol Imaging (2010) 0.93
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs (2010) 0.91
Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. Cardiovasc Res (2014) 0.90
Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol (2011) 0.90
Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis (2007) 0.90
Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol (2010) 0.89
Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent. PLoS One (2010) 0.88
Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res (2012) 0.87
Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J (2009) 0.86
Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins. Bioconjug Chem (2015) 0.86
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res (2012) 0.86
A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs (2010) 0.86
Integrin Regulation of Epidermal Functions in Wounds. Adv Wound Care (New Rochelle) (2014) 0.85
Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther (2013) 0.85
Current available therapies and future directions in the treatment of malignant gliomas. Biologics (2009) 0.83
Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5. PLoS One (2014) 0.83
In vitro evaluation of functional interaction of integrin alphavbeta3 and matrix metalloprotease-2. Mol Pharm (2009) 0.83
Molecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance. Neuro Oncol (2013) 0.83
Recombinant disintegrin (r-Cam-dis) from Crotalus adamanteus inhibits adhesion of human pancreatic cancer cell lines to laminin-1 and vitronectin. J Venom Res (2015) 0.82
Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein. J Biol Chem (2011) 0.82
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. J Clin Oncol (2015) 0.81
Integrin-targeting block copolymer probes for two-photon fluorescence bioimaging. Biomacromolecules (2010) 0.81
Gene expression profiling of the anti-glioma effect of Cilengitide. Springerplus (2013) 0.81
Contemporary murine models in preclinical astrocytoma drug development. Neuro Oncol (2014) 0.81
c-Abl is an upstream regulator of acid sphingomyelinase in apoptosis induced by inhibition of integrins αvβ3 and αvβ5. PLoS One (2012) 0.80
Cilengitide, a small molecule antagonist, targeted to integrin αν inhibits proliferation and induces apoptosis of laryngeal cancer cells in vitro. Eur Arch Otorhinolaryngol (2014) 0.80
Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med (2009) 0.80
End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma. Neuro Oncol (2015) 0.79
Surgical impact on brain tumor invasion: a physical perspective. Ann Surg Innov Res (2008) 0.79
Cancer: a profit-driven biosystem? Med Hypotheses (2008) 0.78
Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β4 expression. Oncotarget (2015) 0.78
A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells. Int J Nanomedicine (2013) 0.78
Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther (2009) 0.78
New agents targeting angiogenesis in glioblastoma. Chemother Res Pract (2011) 0.77
Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. J Cancer Res Clin Oncol (2013) 0.77
Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. Cancer Res (2015) 0.76
Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. Nanomaterials (Basel) (2015) 0.75
Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice. Dis Model Mech (2012) 0.75
Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET. EJNMMI Res (2014) 0.75
The changing face of brain tumours. Preface. Br J Radiol (2011) 0.75
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget (2016) 0.75
Talin Modulation by a Synthetic N-Acylurea Derivative Reduces Angiogenesis in Human Endothelial Cells. Int J Mol Sci (2017) 0.75
The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer. Mol Pharmacol (2016) 0.75
The role of myosin II in glioma invasion: A mathematical model. PLoS One (2017) 0.75
New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics (2017) 0.75
Brain invasion in Meningiomas - Clinical considerations and impact of neuropathological evaluation: A systematic Review. Neuro Oncol (2017) 0.75
Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. Oncol Lett (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Integrins: a family of cell surface receptors. Cell (1987) 21.14
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 8.23
Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol (1996) 4.18
Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A (1987) 4.17
Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest (1991) 2.32
Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery (2001) 2.30
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery (2001) 1.90
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol (2005) 1.86
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Platelet-derived growth factor in human glioma. Glia (1995) 1.71
Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol (1996) 1.53
Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol (2000) 1.29
Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem (1998) 1.20
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging (2004) 1.14
Recurrent malignant glioma in adults. Curr Treat Options Oncol (2002) 1.11
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med (2011) 13.18
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
The developmental transcriptome of Drosophila melanogaster. Nature (2010) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Complete Khoisan and Bantu genomes from southern Africa. Nature (2010) 9.06
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
Abnormal spine morphology and enhanced LTP in LIMK-1 knockout mice. Neuron (2002) 4.18
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 4.05
iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell (2009) 4.04
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell (2011) 3.81
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Synthetic spike-in standards for RNA-seq experiments. Genome Res (2011) 3.58
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol (2008) 3.50
LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell (2009) 3.34
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol (2007) 3.34
Label-free oxygen-metabolic photoacoustic microscopy in vivo. J Biomed Opt (2011) 3.16
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A (2011) 3.14
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem (2008) 3.01
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Demasculinization of X chromosomes in the Drosophila genus. Nature (2007) 2.85
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 2.67
Erythroid GATA1 function revealed by genome-wide analysis of transcription factor occupancy, histone modifications, and mRNA expression. Genome Res (2009) 2.64
Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat Nanotechnol (2007) 2.61
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res (2006) 2.56
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev (2007) 2.56
Ecology. Importing timber, exporting ecological impact. Science (2005) 2.54
Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol (2006) 2.53
HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J (2006) 2.52
The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev (2007) 2.43
Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc Natl Acad Sci U S A (2011) 2.39
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol (2003) 2.38
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
Evolution of protein-coding genes in Drosophila. Trends Genet (2008) 2.36
COP1 and ELF3 control circadian function and photoperiodic flowering by regulating GI stability. Mol Cell (2008) 2.34
Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell (2013) 2.32
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol (2003) 2.30
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res (2008) 2.22
The role of myosin II in glioma invasion of the brain. Mol Biol Cell (2008) 2.20
Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med (2011) 2.18
Replacement of Oct4 by Tet1 during iPSC induction reveals an important role of DNA methylation and hydroxymethylation in reprogramming. Cell Stem Cell (2013) 2.17
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev (2010) 2.14
Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol (2007) 2.14
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology (2014) 2.08
Dynamics of the epigenetic landscape during erythroid differentiation after GATA1 restoration. Genome Res (2011) 2.07
Saccharomyces cerevisiae Mre11/Rad50/Xrs2 and Ku proteins regulate association of Exo1 and Dna2 with DNA breaks. EMBO J (2010) 2.04
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol (2004) 2.03
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
Mean arterial pressure required for maintaining patency of extracranial-to-intracranial bypass grafts: an investigation with computational hemodynamic models-case series. Neurosurgery (2012) 2.02
Genetic diversity and population structure of the endangered marsupial Sarcophilus harrisii (Tasmanian devil). Proc Natl Acad Sci U S A (2011) 1.99
The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer (2009) 1.98
Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res (2006) 1.97
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J (2005) 1.94
RSC mobilizes nucleosomes to improve accessibility of repair machinery to the damaged chromatin. Mol Cell Biol (2006) 1.94
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
Arabidopsis CULLIN4 Forms an E3 Ubiquitin Ligase with RBX1 and the CDD Complex in Mediating Light Control of Development. Plant Cell (2006) 1.92
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg (2009) 1.91
Mechano-electronic superlattices in silicon nanoribbons. ACS Nano (2009) 1.91
Lymphocyte-specific compensation for XLF/cernunnos end-joining functions in V(D)J recombination. Mol Cell (2008) 1.91
Alignment of optical maps. J Comput Biol (2006) 1.88
Synaptic transmission and plasticity in the absence of AMPA glutamate receptor GluR2 and GluR3. Neuron (2003) 1.87
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res (2003) 1.79
Ynamides: a modern functional group for the new millennium. Chem Rev (2010) 1.77
MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology (2013) 1.77
Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology (2010) 1.75
Isoflurane anesthesia induced persistent, progressive memory impairment, caused a loss of neural stem cells, and reduced neurogenesis in young, but not adult, rodents. J Cereb Blood Flow Metab (2010) 1.75
Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates. J Clin Microbiol (2006) 1.71
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.70
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.69
MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett (2008) 1.68
Long range allosteric control of cytoplasmic dynein ATPase activity by the stalk and C-terminal domains. J Biol Chem (2005) 1.68
Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods (2012) 1.67
Size-dependent composition and molar extinction coefficient of PbSe semiconductor nanocrystals. ACS Nano (2009) 1.66